Silibinin plus standard treatment for newly diagnosed glioblastoma
Part of Cancer clinical trials.
This trial tests whether adding the supplement silibinin (milk thistle extract) to the usual radiation and chemotherapy can help people with a certain type of aggressive brain cancer live longer. The study is for patients whose tumor tests positive for a protein called STAT3 and whose cancer has not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been recently diagnosed with glioblastoma, a type of brain tumor, and your tumor must test positive for a protein called STAT3.
- You should start treatment with radiation and chemotherapy within 7 weeks after surgery, and your tumor must not have progressed after surgery.
- You must have good overall health (able to care for yourself and be up and about more than 50% of the time).
- Your blood counts, liver and kidney function must be within certain safe ranges before starting treatment.
- You cannot have any other active cancer or serious health problems that would interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a more intense chemotherapy plan for people with glioblastoma who had only partial removal of their tumor or whose tumor grew back quickly. The goal is to see if this approach can improve outcomes.
This early-phase study tests whether liposomal curcumin, added to standard radiation plus temozolomide, can improve treatment outcomes in newly diagnosed high-grade gliomas. It focuses on safety and how well the treatment can be given with the usual therapy plan.
This trial tests whether adding the study drug azeliragon to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma. The study will also look at how the tumor responds to the added drug.
This study tests whether a new drug called MT-125, combined with standard radiation and chemotherapy, is safe and effective for patients with a specific type of brain tumor (glioblastoma) that has a particular genetic feature (MGMT methylation). The goal is to see if this combination helps patients live longer without serious side effects.
This trial tests a new drug combination for people with newly diagnosed glioblastoma, a type of brain cancer. It adds an immunotherapy drug (adebrelimab) to standard chemotherapy, and some participants also receive hyperbaric oxygen therapy, which may help the treatment work better.
This trial tests adding ruxolitinib, a targeted drug, to the standard radiation and chemotherapy for newly diagnosed glioblastoma. It aims to see if this combination helps people live longer without their cancer growing.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.